With regard to these results, studies in murine models of melanoma, colorectal cancer and AML have analyzed checkpoint co-blockades, and demonstrated greater T cell responses following TIM-3 and PD-1 co-blockades compared to PD-1 inhibition alone [36,47,48]. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.